Estrella Immunopharma, Inc.

Estrella Immunopharma (ESLA) has recorded zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in our monitoring window. However, a short observation period provides limited visibility into structural risks; the company's financing history, equity dilution trajectory, and longer-term filing patterns may reveal material context absent from recent headlines. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores, contextualizes any 8-K activity, and flags AI-detected risk signals across the capital structure. The full $49 Report adds quantified dilution metrics, 12-month event history, financing-stage assessment, and AI risk signals to complete the picture.